Date published: 2026-6-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

Notch 1 Inhibitors

Notch 1 inhibitors belong to a distinctive class of chemical compounds that primarily target the Notch signaling pathway. This pathway plays a pivotal role in various cellular processes, including proliferation, differentiation, and cell fate determination. Notch signaling involves interactions between transmembrane receptors, such as the Notch 1 receptor, and their ligands. These interactions initiate a complex series of proteolytic cleavage events, ultimately leading to the release of the Notch intracellular domain (NICD). The NICD then translocates to the nucleus, where it interacts with transcription factors and co-activators, modulating the expression of numerous target genes. Structurally, Notch 1 inhibitors are designed to specifically interfere with the activation of the Notch pathway by targeting key elements within the signaling cascade. Often, these inhibitors function by blocking the cleavage of the Notch receptor, preventing the release of the NICD and subsequent downstream effects. This class of compounds can exhibit diverse chemical structures, which enables researchers to tailor their design to enhance specificity and efficacy. By disrupting Notch 1 signaling, these inhibitors have the ability to influence cellular processes and responses that are influenced by Notch pathway activity. Through careful modulation of the signaling cascade, Notch 1 inhibitors offer a tool to investigate the fundamental roles of the Notch pathway in various biological contexts, contributing to a deeper understanding of cellular behavior and development. In summary, Notch 1 inhibitors represent a class of chemical compounds designed to perturb the Notch signaling pathway, which plays a critical role in regulating a wide array of cellular processes. Through the inhibition of specific molecular events within the pathway, these compounds offer researchers a means to manipulate cellular behavior and study the intricate mechanisms underlying developmental and physiological processes.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

DAPT

208255-80-5sc-201315
sc-201315A
sc-201315B
sc-201315C
5 mg
25 mg
100 mg
1 g
$40.00
$120.00
$480.00
$2141.00
47
(3)

DAPT inhibits γ-secretase, an enzyme responsible for the cleavage of Notch receptors. This prevents the release of the Notch intracellular domain (NICD) and subsequent activation of Notch signaling, crucial in cellular differentiation and development.

RO-4929097

847925-91-1sc-364602
sc-364602A
10 mg
50 mg
$439.00
$1417.00
1
(1)

RO4929097 is a γ-secretase inhibitor that blocks the proteolytic cleavage of Notch receptors, preventing the release of the active Notch intracellular domain (NICD). This disrupts Notch signaling, affecting cell fate determination and tissue homeostasis.

PF-3084014

1290543-63-3sc-507501
5 mg
$130.00
(0)

PF-03084014 is a γ-secretase inhibitor that interferes with Notch signaling by blocking the cleavage of Notch receptors. This inhibits the release of NICD and alters cellular processes like differentiation and proliferation, making it a potential anti-cancer agent.

MK-0752

471905-41-6sc-364534
sc-364534A
10 mg
50 mg
$592.00
$1550.00
(1)

MK-0752 is a γ-secretase inhibitor that targets Notch signaling by preventing the cleavage of Notch receptors. This inhibits the release of NICD and affects cellular differentiation and proliferation, showing potential in cancer therapy and other diseases.

BMS-906024

1401066-79-2sc-507372
10 mg
$3600.00
(0)

BMS-906024 is a selective γ-secretase inhibitor that blocks the cleavage of Notch receptors. This impedes the release of NICD and its downstream signaling, impacting cellular processes like differentiation and growth, offering potential for cancer research.

BMS-708163

1146699-66-2sc-364444
sc-364444A
10 mg
50 mg
$480.00
$1455.00
1
(0)

Avagacestat is a γ-secretase inhibitor that prevents the cleavage of Notch receptors. By inhibiting NICD release, it affects Notch signaling, with potential therapeutic implications in diseases involving aberrant cell differentiation and proliferation, such as cancer.